REFERENCES
- Albain KS, Crowley JJ, Turrisi AT III, Gandara DR, Farrar WB, Clark JI, Beasley KR, Livingston RB. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwestern Oncology Group Phase II Study, SWOG 9019. J Clin Onc. 2002;20:3454–3460.
- Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT 3rd, Weick JK, Lonchyna VA, Presant CA, McKenna RJ, Gandara DR, Fosmire H, Taylor SA, Stelzer KJ, Beasley KR, Livingston RB. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwestern Oncology Group Phase II Study S 8805. J Clin Onc. 1995;13:1880–1892.
- Armstrong E Frankland. Glucosides. In WA Davis and SS Sadtler (Eds.), Allen's commercial organic analysis (2nd ed.), p. 102. Philadelphia: P. Blakiston's Son & Co, 1913.
- Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report. 2008 Dec 10(12):1–23.
- Borchers AT, Keen CL, Stern JS, Gershwin ME. Inflammation and Native American medicine: the role of botanicals. Am J Clin Nutr. 2000;72(2):339–347. Review.
- Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000;7:273–82.
- Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, v3.0 (CTCAE). Bethesda, MD: National Cancer Institute, 2006. Retrieved May 18, 2011, from http://ctep.cancer.gov/protocoldevelopment/electronic_applications/ docs/ctcaev3.pdf
- Ellison NM, Byar DP, Newell GR. Special report on laetrile: the NCI Laetrile Review. Results of the National Cancer Institute's retrospective laetrile analysis. N Engl J Med. 1978;299(10):549–552.
- Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, Hall SD. The effect of Echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther. 2004;75:89–100.
- Laetrile (apricot kernel) Full Monograph. Natural Medicines Comprehensive Database Web site. Retrieved May 18, 2011, from http://naturaldatabase.therapeuticresearch.com. Stockton, CA: Therapeutic Research Faculty, April 2011.
- Moertel CG, Fleming TR, Rubin J, Kvols LK, Sarna G, Koch R, Currie VE, Young CW, Jones SE, Davignon JP. A clinical trial of amygdalin (laetrile) in the treatment of human cancer. N Engl J Med. 1982;306:201–206.
- Relling MV, Evans R, Dass C, Desiderio DM, Nemec J. Human cytochrome P450 metabolism of teniposide and etoposide. J Pharmacol Exp Ther. 1992;261:491–496.
- Rodman JH, Murry DJ, Madden T, Santana VM. Pharmacokinetics of high dose etoposide and the influence of anticonvulsants in pediatric cancer patients. Clin Pharmacol Ther. 1992;51:156.
- Teva. Toposar (etoposide) package insert. Irvine, CA, 2007.
- van Maanen JM, Lafleur MV, Mans DR, van den Akker E, de Ruiter C, Kootstra PR, Pappie D, de Vries J, Retèl J, Pinedo HM. Effects of the ortho-quinone and catechol of the antitumor drug VP-16-213 on the biological activity of single-stranded and double-stranded phi X174 DNA. Biochem Pharmacol. 1988;37:3579–3589.
- Yong WP, Desai AA, Innocenti F, Ramirez J, Shepard D, Kobayashi K, House L, Fleming GF, Vogelzang NJ, Schilsky RL, Ratain MJ. Pharmocokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2007;60:811–819.